ARQ 621

Eg5 inhibitor CAS# 1095253-39-6

ARQ 621

Catalog No. BCC6534----Order now to get a substantial discount!

Product Name & Size Price Stock
ARQ 621: 5mg $161 In Stock
ARQ 621: 10mg Please Inquire In Stock
ARQ 621: 20mg Please Inquire Please Inquire
ARQ 621: 50mg Please Inquire Please Inquire
ARQ 621: 100mg Please Inquire Please Inquire
ARQ 621: 200mg Please Inquire Please Inquire
ARQ 621: 500mg Please Inquire Please Inquire
ARQ 621: 1000mg Please Inquire Please Inquire
Related Products
  • Marimastat

    Catalog No.:BCC2118
    CAS No.:154039-60-8
  • Ro 32-3555

    Catalog No.:BCC2377
    CAS No.:190648-49-8
  • CP 471474

    Catalog No.:BCC2373
    CAS No.:210755-45-6
  • SB-3CT

    Catalog No.:BCC5486
    CAS No.:292605-14-2
  • NSC 405020

    Catalog No.:BCC2120
    CAS No.:7497-07-6
  • ARP 101

    Catalog No.:BCC2371
    CAS No.:849773-63-3

Quality Control of ARQ 621

Number of papers citing our products

Chemical structure

ARQ 621

3D structure

Chemical Properties of ARQ 621

Cas No. 1095253-39-6 SDF Download SDF
PubChem ID 25110841 Appearance Powder
Formula C28H24Cl2FN5O2 M.Wt 552.43
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble in DMSO
Chemical Name N-(3-aminopropyl)-N-[(1R)-1-(3-anilino-7-chloro-4-oxoquinazolin-2-yl)but-3-ynyl]-3-chloro-2-fluorobenzamide
SMILES C#CCC(C1=NC2=C(C=CC(=C2)Cl)C(=O)N1NC3=CC=CC=C3)N(CCCN)C(=O)C4=C(C(=CC=C4)Cl)F
Standard InChIKey UPJSUQWHUVLLNW-XMMPIXPASA-N
Standard InChI InChI=1S/C28H24Cl2FN5O2/c1-2-8-24(35(16-7-15-32)27(37)21-11-6-12-22(30)25(21)31)26-33-23-17-18(29)13-14-20(23)28(38)36(26)34-19-9-4-3-5-10-19/h1,3-6,9-14,17,24,34H,7-8,15-16,32H2/t24-/m1/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

ARQ 621 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

ARQ 621 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of ARQ 621

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.8102 mL 9.0509 mL 18.1018 mL 36.2037 mL 45.2546 mL
5 mM 0.362 mL 1.8102 mL 3.6204 mL 7.2407 mL 9.0509 mL
10 mM 0.181 mL 0.9051 mL 1.8102 mL 3.6204 mL 4.5255 mL
50 mM 0.0362 mL 0.181 mL 0.362 mL 0.7241 mL 0.9051 mL
100 mM 0.0181 mL 0.0905 mL 0.181 mL 0.362 mL 0.4525 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on ARQ 621

ARQ 621 is a novel, allosteric, potent and selective inhibitor of Eg5. Eg5 is a member of the mitotic kinesin superfamily which plays a key role in mitosis. Eg5 is essential for the dynamic organization of the mitotic spindle. Over-expression of Eg5 leads to genomic instability and tumor formation [1].

In vitro: In human liver microsomes, t1/2 of ARQ 621 was 53 min. The t1/2 value of ARQ 621 in male and female mouse, rat, dog and monkey liver microsomes was 43, 53, 56, 53, 47, 44, 36, and 32 minutes, respectively [1]. IC50 value of ARQ 621 for CYP 1A2, 2C9, 2D6, 3A4, 2C19, and 2C8 was >20, >20, >20, 4.1, 4.0, and 15 ?M, respectively. ARQ 621 showed anti-tumor activity with potencies in the low nanomolar range across a range of human solid and hematological malignanciescancer cell types such as colon, NSCLC, gastric, and hematologic cancer cell lines [1].

In vivo: Oral administration of ARQ 621 showed that the bioavailability of ARQ 621 was approximately 9% [1].

Clinical trial: ARQ 621 was currently being tested in a Phase I clinical trial in cancer patients. ARQ 621 (10 mg/m2/week) was administered weekly intravenously over 1-2 hours. Adverse events emerged in 95.9% patients. The main drug-related side-effects were fatigue, acute intravascular hemolysis, and abdominal pain. ARQ 621 appeared to be well tolerated at the weekly dose of 280 mg/m2[2,3].

References:
Savage R E, Zhong C, Hall T, et al.  In vitro ADME properties of ARQ 621: A specific Eg5 inhibitor[J]. Cancer Research, 2010, 70(8 Supplement): 5783-5783.
Rosen L, Chen L C, Iyengar T, et al.  ARQ 621, a novel potent and selective inhibitor of Eg5: preclinical data and early results from a clinical phase 1 study[J]. Cancer Research, 2010, 70(8 Supplement): 2750-2750.
Chen L C, Rosen L S, Iyengar T, et al.  First-in-human study with ARQ 621, a novel inhibitor of Eg5: Final results from the solid tumors cohort[C]//ASCO Annual Meeting Proceedings. 2011, 29(15_suppl): 3076.

Featured Products
New Products
 

Description

ARQ 621 is an allosteric, and selective Eg5 mitotic motor protein inhibitor. Phase 1.

Keywords:

ARQ 621,1095253-39-6,Natural Products,Kinesin, buy ARQ 621 , ARQ 621 supplier , purchase ARQ 621 , ARQ 621 cost , ARQ 621 manufacturer , order ARQ 621 , high purity ARQ 621

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: